Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the
standard treatment Neoral® for a treatment period of 6 months in stable renal allograft
transplant recipients with respect to drug levels, dosage, and acute graft rejection and
other adverse events.